Disopyramide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Disopyramide: From Antiarrhythmic Use to Tourette Syndrome
One-Sentence Summary
Disopyramide is a class Ia antiarrhythmic drug that is currently marketed in the US. The TxGNN model predicts it may be effective for Tourette syndrome, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Antiarrhythmic (the approved indication text is not captured in the source data) |
| Predicted New Indication | Tourette syndrome |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 11 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, disopyramide is a sodium-channel-blocking class Ia antiarrhythmic with anticholinergic activity.
No plausible mechanistic link to Tourette syndrome has been identified. Sodium-channel blockade in cardiac tissue does not obviously connect to the neurological basis of tics. The very high TxGNN score is best read as a graph-based signal, not as pharmacological support.
The other top-ranked predictions are mostly neurodevelopmental or psychiatric conditions (ADHD, trichotillomania, developmental disorders). This suggests the model is clustering on graph-neighborhood similarity. Anticholinergic effects and QT-prolongation risk would also be concerns in these populations.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA018655 | Norpace CR | Capsule, extended release | Pfizer Laboratories Div Pfizer Inc |
| NDA017447 | Norpace | Capsule, gelatin coated | Pfizer Laboratories Div Pfizer Inc |
| ANDA070102 | Disopyramide Phosphate | Capsule | Teva Pharmaceuticals USA, Inc. |
| ANDA070173 | Disopyramide Phosphate | Capsule | Dr. Reddy’s Laboratories Inc. |
All marketed forms are oral.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support and no identifiable mechanistic link. Disopyramide’s anticholinergic and proarrhythmic liabilities make speculative use in a neurological or pediatric population hard to justify.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are required for safety screening
- Mechanism of action data, for example from DrugBank
- Approved indication text from the current labels
- Any preclinical or clinical signal linking sodium-channel blockade or anticholinergic activity to tic disorders
Note on other predictions: Multifocal atrial tachycardia (rank 9) is the only prediction with a mechanistically plausible link and one indirect paper. That paper (PMID 7418495) concerns lorcainide, not disopyramide, so it does not support the prediction. This is a candidate for further review, not for advancement.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.